Company profile: Enterome
1.1 - Company Overview
Company description
- Provider of clinical-stage immunomodulatory drugs for cancer and immune diseases, offering OncoMimics, a cancer immunotherapy using bacterial peptides to mimic tumor antigens, with Phase 2 candidates EO2401 (glioblastoma/adrenal), EO2463 (indolent NHL) and EO4010 (third-line colorectal), and EndoMimics oral bioactives for inflammatory/autoimmune diseases, including EB1010 for food allergies and IBD.
Products and services
- OncoMimics™: A cancer immunotherapy platform using bacterial peptides to mimic tumor-associated antigens, generating strong, durable immune responses across solid and liquid tumors with an off-the-shelf, easy-to-manufacture technology
- EndoMimics™: A platform creating bioactive drugs that mirror human hormones or cytokines to modulate immunity in inflammatory and autoimmune diseases, employing oral administration
- EO2401: An OncoMimics™ immunotherapy candidate in Phase 2 for glioblastoma and adrenal tumors, engineered to induce immune responses against tumor cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enterome
TraceLink
HQ: United States
Website
- Description: Provider of a SaaS network creation platform that connects people, companies, systems, and processes to build integrated business ecosystems with multienterprise applications, enabling digitalization, customer-centric agility and resiliency across end-to-end supply networks and leveraging the collective intelligence of entire industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TraceLink company profile →
AiCure
HQ: United States
Website
- Description: Provider of AI-driven data analytics to understand patient response to treatments, offering a regulatory-compliant platform to capture and analyze digital biomarkers for predicting participant behavior and treatment response, a Patient Connect mobile app with computer vision for real-time dosing guidance and adherence, site services supporting clinical operations and engagement, and OpenDBM for open-source access to digital biomarker algorithms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCure company profile →
Aparito
HQ: United Kingdom
Website
- Description: Provider of an eCOA platform (Atom5) that digitises clinical trials and captures real-world patient data via video assessments, ePROs, wearables, telemedicine, and eConsent, delivering real-time insights to clinical teams. Part 11, GDPR and HIPPA compliant, supporting patient-centric trials at scale in 193 countries and 125 languages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aparito company profile →
Evolved By Nature
HQ: United States
Website
- Description: Provider of Activated Silk biotechnology that creates biobased molecules from natural silk protein to enhance and protect surfaces across therapeutics, textiles and personal care. Offerings include a leather biofinishing system replacing harmful petrochemicals, textile finishing agents for nylon and polyester, skincare ingredients supporting the skin barrier and collagen, and biosurfactants for petrochemical-free soaps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evolved By Nature company profile →
System Analytic
HQ: United Kingdom
Website
- Description: Provider of an ecosystem of innovative digital tools and world-class services to support the entire KOL/HCP engagement cycle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full System Analytic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enterome
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enterome
2.2 - Growth funds investing in similar companies to Enterome
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enterome
4.2 - Public trading comparable groups for Enterome
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →